Articles tagged with Cancer Immunotherapy
Researchers have discovered an experimental mRNA vaccine that can boost tumor-fighting effects of immunotherapy, sparking a new approach to battling many types of treatment-resistant tumors. The study found that pairing the test vaccine with common anticancer drugs triggered a strong antitumor response.
The inaugural ESMO Targeted Anticancer Therapies (TAT) Asia Congress 2025 will convene a diverse group of stakeholders to foster collaboration and accelerate the development of innovative cancer therapies. The congress aims to become a catalyst for global collaboration and innovation in oncology.
Researchers developed a biomimetic physical barrier that temporarily blocks T cell-tumor cell interactions, delaying exhaustion and enabling a stronger immune response. The breakthrough strategy can potentially be combined with other immunotherapeutic approaches to enhance treatment efficacy.
A new treatment approach using cyclophosphamide has been found to prevent most graft-versus-host disease in mismatched transplants. The study shows that 80% of patients are alive after a year, similar to outcomes seen in fully matched transplants.
Researchers developed a novel immunotherapy that disrupts the IL-33/IL1RL1 signaling loop to boost immune function and improve survival in leukemia patients. The treatment targeted leukemia stem cells, reducing relapse rates and improving survival without major side effects.
A new study from Uppsala University found that most men with prostate cancer who receive recommended treatment have a good prognosis, with a lower risk of dying from prostate cancer than other causes. The study's findings highlight the importance of assessing a patient's life expectancy in choosing an appropriate treatment strategy.
A new study published in the Journal of Hepatology shows that durvalumab plus GemCis significantly improves overall survival for patients with advanced biliary tract cancer. The three-year follow-up analysis found that over twice as many participants treated with durvalumab plus GemCis remained alive compared to those treated with a pl...
A Phase II study found that 87% of patients with stage III melanoma remained alive and disease-free four years after treatment with nivolumab and relatlimab. Researchers identified unique biomarkers associated with better outcomes, including high TIGIT levels and low B7-H3 levels.
A new study from the University of Pittsburgh shows exercise improves cancer outcomes and enhances response to immunotherapy in mice by reshaping the gut microbiome. The research found that a specific compound called formate, produced by gut bacteria in exercised mice, was associated with better outcomes in patients with melanoma.
Researchers identify new group of immune cells driving autoimmune attack on insulin-producing cells in pancreas during cancer immunotherapy. JAK inhibitors, already FDA-approved for psoriasis and arthritis, show potential to prevent and even reverse type 1 diabetes in preclinical models.
A new dual CAR-T cell therapy has been developed to target T-ALL, showing high efficacy and safety. The treatment targets two antigens simultaneously, making it more effective than previous therapies. Experimental results demonstrate its ability to control the disease in both laboratory and animal models, with an excellent safety profile.
Researchers have identified a single genetic difference in Fas Ligand, an immune protein, that makes it vulnerable to being disabled by plasmin, a tumor-associated enzyme. This vulnerability seems unique to humans and may contribute to the effectiveness of certain cancer treatments.
Scientists have developed a miniature device that mimics human bone marrow and immune environment, enabling predictive testing of cancer immunotherapy success in patients. The device recreates three regions of bone marrow where leukemia develops and retains the complex immune environment of the tissue.
Scientists have discovered that CD4 T cells can target tumour cells with high efficiency, expanding the pool of patients who could benefit from this therapy. A clinical trial is currently preparing to test this approach in adults and children with various types of cancer.
This study identifies pre-neadjuvant carcinoembryonic antigen (CEA) and neutrophil-to-lymphocyte ratio (NLR) as significant predictors of postoperative recurrence-free survival in non-small cell lung cancer (NSCLC) patients after neoadjuvant therapy. Smoking history is also a predictor of recurrence in LUSC patients.
The BRACELET-1 trial demonstrated a 20% objective response rate and 12.1-month progression-free survival for patients with unresectable HR+ HER2- tumors, suggesting that adding pelareorep to paclitaxel chemotherapy warrants further investigation in metastatic breast cancer.
CIK cell therapy improved overall and progression-free survival for patients with colorectal cancer, regardless of disease stage. Serum CEA levels can predict treatment response, paving the way for a simple blood test.
The new NCCN Guidelines Navigator tool offers an interactive platform for accessing evidence-based guidelines, facilitating easier searching and navigation. The initiative aims to improve patient care and outcomes by providing healthcare professionals with up-to-date recommendations.
A new study reveals that cancer-fighting immunotherapy drugs may offer benefits to organ transplant recipients with advanced cancer when carefully managed. The study found that about one in three patients responded positively to treatment within a year, with improved survival outcomes comparable to the general population.
Researchers at MD Anderson have made significant progress in treating non-small cell lung cancer (NSCLC) by combining chemotherapy, immunotherapy, and surgery. They found that pre-surgical combination therapy showed promising results, with high rates of pathological complete response and major pathological response.
Researchers at NYU Langone Health discovered that a specific biological pathway explains why many patients with deadly melanoma do not respond to latest cancer treatments. The study found therapeutic targets that could limit melanoma growth in patients with NF1 mutations, suggesting a novel approach for treatment.
Researchers at Nagoya University have created CAR-T cells that recognize and target the Eva1 protein on cancer cells, effectively eliminating tumors in lab mice. The treatment is designed to be safer by ignoring healthy cells with low amounts of Eva1.
A recent study found that MET mutations are associated with enhanced tumor immunogenicity, increased immune cell infiltration, and improved response rates to immune checkpoint blockade. Certain single base substitutions identified as robust predictive biomarkers for survival in pan-cancer immunotherapy.
Researchers found a specific genetic mutation, MT haplogroup T, in patients who did not respond to immune checkpoint inhibitors. The study showed that these patients had more underdeveloped T cells and increased resilience to reactive oxygen species, stunting their attack on cancer cells.
Researchers identified a link between the loss of Y chromosome in white blood cells and reduced ability to kill cancer cells. This finding may explain why men with loss of Y have higher cancer risks and poorer outcomes. The study provides insights into how this genetic change affects immune system function.
Combining immunotherapy drug dostarlimab with standard chemotherapy improved survival and reduced symptoms in patients with advanced endometrial cancer. Patients lived up to 5.5 months longer with fewer side effects, outweighing risks.
A global clinical trial led by Irish cancer specialist Prof. Patrick Forde shows that immunotherapy with chemotherapy before lung cancer surgery reduces the risk of cancer returning and improves long-term survival. The study found that patients who received immunotherapy plus chemotherapy had improved outcomes compared to those who rec...
A phase 3 trial of patients with surgically resected stage 3 dMMR colon cancer found that adding an immune checkpoint inhibitor (atezolizumab) to standard chemotherapy improved disease-free survival by 50% compared to chemotherapy alone. The study results provide new evidence for a treatment approach in this high-risk patient population.
A new study found that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colon cancer resulted in a 50% reduction in cancer recurrence and death compared to chemotherapy alone. The treatment combination showed significant benefits for patients with deficient DNA mismatch repair genetic makeup.
A phase I clinical trial demonstrates that dual-target CAR T cell therapy can reduce tumor size in nearly two-thirds of patients with recurrent glioblastoma, a notoriously aggressive brain cancer. The therapy also shows signs of long-term immune system activation and potential for extended tumor stability.
Assistant professor of electrical and computer engineering Natasa Miskov-Zivanov is receiving a $581,503 NSF CAREER Award for her project that leverages AI to design more effective lymphocytes for cancer immunotherapies. The system aims to accelerate the process of designing new therapeutic cell designs.
In an international clinical trial, a new CAR-T cell immunotherapy demonstrated promising results against aggressive blood cancers, including T cell acute lymphoblastic leukemia and T cell lymphoblastic lymphoma. Most patients who received the full dose of cells achieved full remission, with response rates ranging from 70-90%.
Researchers at Memorial Sloan Kettering Cancer Center have discovered that Bacillus Calmette-Guérin (BCG) therapy reprograms and amplifies cells in the bone marrow, enhancing the innate immune system's ability to combat cancer. This breakthrough could lead to improved immunotherapies for various cancers.
Researchers at Weill Cornell Medicine have made new discoveries about BCG therapy, which has been shown to reprogram and amplify immune cells in the bone marrow, boosting the body's ability to fight cancer. The findings could lead to improved immunotherapies for various types of cancer.
Researchers developed a dual action immunotherapy using CAR-T cells targeting CD19 and CD22 proteins in B-ALL cancer cells, increasing the efficacy of treatment and reducing relapse rates.
Researchers identify five distinct immunotypes in tongue squamous cell carcinoma, shedding light on why current immunotherapies fail. The study's findings highlight the need for immune-based assessments to guide treatment decisions and suggest a new approach to personalized medicine.
Researchers discovered a novel mechanism by which glioblastoma cells exploit astrocytes to evade immune responses. The study highlights an astrocyte-driven mechanism used by GBM to escape protective immune responses and could guide novel immunotherapies for the treatment of this aggressive brain cancer.
A UCLA study found that selective serotonin reuptake inhibitors (SSRIs) can significantly enhance the ability of T cells to fight cancer and suppress tumor growth across various cancer types in mouse and human tumor models. SSRIs increased access to serotonin signals, making killer T cells happier and more effective at killing cancer c...
A new study at the University of Turku identified conditions under which Bexmarilimab activates the immune system against cancer. The drug was shown to trigger B cell-mediated immune responses in healthy tissue adjacent to tumors. This could lead to more accurate patient selection and improved treatment outcomes.
Researchers found that aging impairs CAR-T cell function and antitumor activity due to lower NAD levels. Rejuvenating aged cells with NAD-boosting compounds improves their effectiveness.
A new analysis of over 18,000 cancer cases suggests that obese patients may fare better after immunotherapy treatment, with improved overall survival rates. The study's findings raise intriguing questions about the role of obesity in immunotherapy effectiveness and highlight the need for further research to understand this phenomenon.
Researchers at A.C.Camargo Cancer Center developed a more powerful version of CAR-T cells by inhibiting the epigenetic alterations that made them inefficient against non-Hodgkin's lymphoma and acute lymphoblastic leukemia. This modification resulted in improved treatment efficacy, tumor elimination, and reduced side effects.
UT Dallas bioengineers have created an enhanced light-activated immunotherapy approach to target advanced stomach cancer. Lab-designed molecules are primed with far-red or near-infrared light to activate the immune system against stubborn cancer cells, reducing side effects.
Researchers found that denosumab increases tumour-infiltrating immune cells in early-stage breast cancer patients, particularly in type B luminal tumours. This increase is associated with a potential boost to the anti-tumor immune response and offers a valuable avenue for clinical interest.
A new Stanford Medicine-led study reveals that CAR-T cell therapy causes mild cognitive impairments in cancer patients, independent of other treatments. Researchers identified the cellular mechanism behind this effect and found strategies to reverse it.
Researchers discovered 500 cryptic peptides found only in pancreatic tumors, which could be targeted by vaccines or engineered T cells to attack the cancer. The peptides were identified using immunopeptidomics and shown to slow down tumor growth in mice.
A new strategy for treating B-cell lymphoma has shown promising results with a next-generation CAR T cell therapy that incorporates IL18. The treatment achieved high remission rates of 81% and complete remission in 52%, with some patients experiencing durable responses lasting two years or more.
Researchers have successfully tested a CRISPR/Cas9 gene-editing technique to enhance the immune system's fight against advanced gastrointestinal (GI) cancers. The treatment showed encouraging signs of safety and potential effectiveness in patients with stage IV colorectal cancer, halting tumor growth and even achieving complete responses.
A USC team has developed an advanced platform to analyze chimeric antigen receptor (CAR) T cells, revealing how their manufacturing conditions impact effectiveness. The tool uses laser technology to analyze 36 characteristics of a single cell, providing a clearer view of CAR T cell behavior.
Adaptive NK cells exhibit tumor-specific immune memory and cytotoxicity in ovarian cancer, making them promising for cancer treatment. The study challenges previous perceptions of NK cells, which have historically been considered only innate immune cells with no memory function against cancer.
A phase 3 clinical trial shows that adding pembrolizumab to standard-of-care therapy increases tumor shrinkage and prolongs cancer-free survival by nearly two years. Patients with locally advanced head and neck cancers benefited from this addition, marking a significant change in standard-of-care for the disease.
Researchers from the University of Cincinnati Cancer Center presented abstracts highlighting contrasting effects of a protein on head and neck, breast, and lung cancers. The study found increased levels of IL-9 in patients with head and neck cancer correlated with decreased survival, while elevated IL-9 was associated with smaller tumo...
The ImmunoVerse podcast features conversations with leading physicians and scientists in immunotherapy, highlighting groundbreaking discoveries and their impact on cancer care. Launched by Moffitt Cancer Center, the podcast aims to spark conversation, inspiration, and hope for those affected by cancer.
A study by Johns Hopkins Medicine found that older adults with cancer benefit equally from immunotherapy treatments as younger patients, with key differences in their immune responses and cells. Researchers hope to develop new therapies tailored to different age groups' needs and improve treatment success.
A subset of patients with non-small cell lung cancer who discontinued immune checkpoint inhibitor therapy due to immune-related adverse events continued to experience long-term disease control. The median post-discontinuation progression-free survival was 12.7 months, and the median post-discontinuation overall survival was 43.7 months.
A survey by Roswell Park Comprehensive Cancer Center found that 65% of Americans are unfamiliar with CAR T-cell therapy, a personalized cancer treatment option. The therapy involves extracting and engineering immune cells to recognize and kill cancer cells, with promising results in treating blood cancers.
Researchers found basal cell carcinomas (BCCs) have an immune-excluded phenotype with minimal HLA-I expression, even in early development. A stem-like quiescent program suppressed APM genes, which could be reversed to enable BCC immunotherapy.
University of Virginia researcher Natasha D. Sheybani has received a $5.5 million grant to advance her research on focused ultrasound technology for breast cancer immunotherapy. Her work aims to enhance the safety, effectiveness, and precision of immunotherapy drugs.
Scientists have discovered a new immunotherapy strategy using type I dendritic cells to activate strong immune responses and generate immune memory against cancer. The treatment helps prevent tumor relapse in mouse models by triggering an immune memory response.
A new clinical trial at the University of Miami Miller School of Medicine is testing a novel combination of immunotherapy drugs and an oncolytic virus to treat high-grade neuroendocrine cancer. The trial aims to find safe combination doses and compare effectiveness with standard-of-care treatment.